文献速递核素与放射性配体治疗骨显像与常规 SPECT

一项随机II期研究:重复镥-188-HEDP联合多西他赛和泼尼松对比单用多西他赛和泼尼松治疗转移至骨的去势抵抗性前列腺癌(CRPC);Taxium II试验

A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-18

这项随机II期研究将88例进行性CRPC伴成骨性骨转移患者随机分为标准治疗组(多西他赛75 mg/m2每3周+泼尼松)和联合治疗组(加用2次镥-188-HEDP,第3周期后40 MBq/kg、第6周期后20 MBq/kg)。意向治疗分析中两组无进展生存期、生存和PSA无差异;探索性符合方案分析中联合组中位总生存期显著更长(33.8个月 vs 21.0个月,p 0.012)。作者结论为联合治疗未延长PFS,观察到的生存获益需进一步研究。

要点

  • 意向治疗分析中联合镥-188-HEDP未改善CRPC患者的无进展生存期、生存或PSA。
  • 探索性符合方案分析中联合组中位总生存期33.8个月 vs 对照组21.0个月(p 0.012)。
  • 基线碱性磷酸酶>220U/L患者联合组中位PFS 9.0个月 vs 6.2个月(log rank p 0.005)。

核心结论

  • 镥-188-HEDP联合多西他赛未延长CRPC患者的无进展生存期;符合方案分析中观察到的生存获益需进一步研究联合化疗与放射性药物的治疗。

研究设计与样本

  • 随机II期研究,纳入进行性CRPC伴成骨性骨转移患者,随机分为标准治疗组42例和联合治疗组46例。
  • 标准治疗为一线多西他赛75 mg/m2每3周+泼尼松;联合组在化疗第3周期后(40 MBq/kg)和第6周期后(20 MBq/kg)接受2次镥-188-HEDP注射。
  • 主要终点为无进展生存期(PFS),定义为PSA、影像学或临床进展;按骨转移范围和医院分层。

主要发现

  • 意向治疗分析中两组PFS、生存和PSA无差异。
  • 探索性符合方案分析中,联合组中位总生存期33.8个月(95%CI 31.75-35.85)vs 对照组21.0个月(95%CI 13.61-28.39),p 0.012。
  • 基线碱性磷酸酶>220U/L患者中,联合组中位PFS 9.0个月(95%CI 3.92-14.08)vs 对照组6.2个月(95%CI 3.08-9.32),log rank p 0.005。
  • I/II级血小板减少在联合组更常见(25% vs 0%)。

局限性

  • 观察到的生存获益来自探索性符合方案分析,作者指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rhenium-188-HEDP is a beta-emitting radiopharmaceutical used for palliation of metastatic bone pain. We investigated whether the addition of rhenium-188-HEDP to docetaxel/prednisone improved efficacy of chemotherapy in patients with CRPC. METHODS: Patients with progressive CRPC and osteoblastic bone metastases were randomised for first-line docetaxel 75 mg/m2 3-weekly plus prednisone with or without 2 injections of rhenium-188-HEDP after the third (40 MBq/kg) and after the sixth (20 MBq/kg) cycle of docetaxel. Primary endpoint was progression-free survival (PFS), defined as either PSA, radiographic or clinical progression. Patients were stratified by extent of bone metastases and hospital. RESULTS: Forty-two patients were randomised for standard treatment and 46 patients for combination therapy. Median number of cycles of docetaxel was 9 in the control group and 8 in the experimental group. Median follow-up was 18.4 months. Two patients from the experimental group did not start treatment after randomisation. In the intention to treat analysis no differences in PFS, survival and PSA became apparent between the two groups. In an exploratory per-protocol analysis median overall survival was significantly longer in the experimental group (33.8 months (95%CI 31.75-35.85)) than in the control group (21.0 months (95%CI 13.61-28.39); p 0.012). Also median PFS in patients with a baseline phosphatase >220U/L was significantly better with combination treatment (9.0 months (95%CI 3.92-14.08) versus 6.2 months (95%CI 3.08-9.32); log rank p 0.005). As expected, thrombocytopenia (grade I/II) was reported more frequently in the experimental group (25% versus 0%). CONCLUSION: Combined treatment with rhenium-188-HEDP and docetaxel did not prolong PFS in patients with CRPC. The observed survival benefit in the per-protocol analysis warrants further studies in the combined treatment of chemotherapy and radiopharmaceuticals.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, et al. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. Eur J Nucl Med Mol Imaging. 2017. PMID: 28421240. doi:10.1007/s00259-017-3673-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。